Unum Therapeutics to Present at Two Upcoming Investor Conferences

April 2, 2019 at 7:00 AM EDT

CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, today announced that Charles Wilson, Chief Executive Officer, will present a corporate overview at two upcoming investor conferences in April:

Jefferies 6th Annual IO Cell Therapy Summit on Friday, April 5, 2019, at 4:25 p.m. ET in Boston, MA

H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9, 2019, at 1:50 p.m. BST / 9:50 a.m. EDT in London, United Kingdom. This presentation will be webcast live, and available for replay on the “Events” section of Unum’s investor relations webpage (investors.unumrx.com/events), where it will be archived for approximately 90 days.

About Unum Therapeutics

Unum Therapeutics is a clinical-stage biopharmaceutical company providing potentially curative T cell therapies to treat a broad range of cancer patients. Unum’s novel proprietary technologies include Antibody-Coupled T cell Receptor (ACTR), a universal, engineered cell therapy intended to be used in combination with a wide range of tumor-specific antibodies to target different tumor types, and Bolt-On Chimeric Receptor (BOXR), an approach for improving T cell functionality in solid tumor cancer applications. Unum has four product candidates currently in Phase I clinical testing, including ACTR707 used in combination with rituximab in adult patients with r/r NHL; ACTR087 used in combination with the novel antibody SEA-BCMA in r/r multiple myeloma; and ACTR707 used in combination with trastuzumab in adult patients with HER2+ advanced cancer.

The Company is headquartered in Cambridge, MA.

Investor Contact:
Stephanie Ascher, 212-362-1200
stephanie@sternir.com  

Media Contact:
Arleen Goldenberg, 202-930-4762
agoldenberg@vergescientific.com 

 

UnumLogo.jpg

Source: Unum Therapeutics Inc.